BRAIN SCIENTIFIC INC.
BRSF evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $745
- Lead Asset:
- neurocap (Approved)
What it means
What to watch
Prepared research question
What matters most for BRSF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$745
Cash Runway
—
Lead Asset
neurocap (Approved)
Next Catalyst
—
Tracking 2 pipeline candidates · 24 clinical trials for BRAIN SCIENTIFIC INC..
Run BRAIN SCIENTIFIC INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BRAIN SCIENTIFIC INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is BRAIN SCIENTIFIC INC.'s lead drug candidate?
BRAIN SCIENTIFIC INC.'s most advanced tracked candidate is neurocap (Approved) for EEG testing.
Who is the CEO of BRAIN SCIENTIFIC INC.?
Mr. Hassan Kotob is the chief executive officer of BRAIN SCIENTIFIC INC. (BRSF).
Where is BRAIN SCIENTIFIC INC. headquartered?
BRAIN SCIENTIFIC INC. (BRSF) is headquartered in Sarasota, FL, United States.
What therapeutic areas does BRAIN SCIENTIFIC INC. focus on?
BRAIN SCIENTIFIC INC. develops therapies across Oncology, Neurology, Cardiovascular, Pain, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.